Home » Stocks » OLMA

Olema Pharmaceuticals, Inc. (OLMA)

Stock Price: $30.51 USD 0.60 (2.01%)
Updated Jun 15, 2021 4:00 PM EDT - Market closed
Market Cap 1.21B
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 40.17M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 15
Last Price $30.51
Previous Close $29.91
Change ($) 0.60
Change (%) 2.01%
Day's Open 30.26
Day's Range 29.22 - 32.77
Day's Volume 565,765
52-Week Range 19.41 - 60.27

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

SAN FRANCISCO, May 18, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development ...

4 weeks ago - GlobeNewsWire

SAN FRANCISCO, May 11, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development ...

1 month ago - GlobeNewsWire

SAN FRANCISCO, April 07, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” NASDAQ: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, developmen...

2 months ago - GlobeNewsWire

SAN FRANCISCO, April 06, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” NASDAQ: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, developmen...

2 months ago - GlobeNewsWire

SAN FRANCISCO, March 17, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” NASDAQ: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, developmen...

2 months ago - GlobeNewsWire

SAN FRANCISCO, March 10, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”), a clinical-stage biopharmaceutical company focused on the discovery, development and commerci...

3 months ago - GlobeNewsWire

SAN FRANCISCO, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” NASDAQ: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development...

3 months ago - GlobeNewsWire

The biotechnology exchange-traded fund SPDR S&P Biotech ETF (NYSE: XBI) is up around 50% in 2020 and Jefferies' managing director Michael Yee says the valuations are not only justified but sustainable i...

Other stocks mentioned: MORF, SDGR
5 months ago - Invezz

SAN FRANCISCO, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”), a clinical-stage biopharmaceutical company focused on the discovery, development and commercia...

6 months ago - GlobeNewsWire

Since going public on Nov. 19, shares of Olema Pharmaceuticals Inc.(NASDAQ:OLMA) have soared past the offering price of $19 per share to over $53, giving the San Francisco-based company a market value o...

6 months ago - GuruFocus

SAN FRANCISCO, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”), a clinical-stage biopharmaceutical company focused on the discovery, development and commercia...

6 months ago - GlobeNewsWire

SAN FRANCISCO, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”), a clinical-stage biopharmaceutical company focused on the discovery, development and commercia...

6 months ago - GlobeNewsWire

About OLMA

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Ph... [Read more...]

Industry
Biotechnology
IPO Date
Nov 19, 2020
Stock Exchange
NASDAQ
Ticker Symbol
OLMA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

The average 12-month stock price forecast for OLMA is 57.50, which is an increase of 88.46% from the latest price.

Price Target
$57.50
(88.46% upside)